This webinar will provide a comprehensive overview of an automated, high-precision non-invasive prenatal testing (NIPT) platform that does not rely on next-generation sequencing or PCR amplification, enabling precise measurement of chromosomal aneuploidies for high performance screening minimizing both false positives, false negatives and no-calls.
In this webinar, three speakers will provide different perspectives on the Vanadis NIPT platform and its implementation in the lab setting.
First, Fredrik Dahl, chief technology officer of Vanadis, will provide a brief outline on the system and will discuss supporting clinical data on both high- and low-risk cohorts. Dr. Dahl will provide details of how Vanadis differs from NGS-based NIPT systems as well as clinical proof-of-principle data.
Glenn Palomaki of the Alpert Medical School at Brown University will then provide an update on an external research study of the Vanadis system in the US. The study, called VALUE (Validation of a Lower Cost Aneuploidy Screen), aims to enroll 2,400 women from the general pregnancy population and 250 high-risk pregnancies. Along with screening performance characteristics (detection rate, false positive rate, and test failure rate), the study is collecting information on turn-around-time, costs of equipment and supplies, and needed training.
Finally, Jérémie Gautier of Cerba Xpert will discuss a validation study using the Vanadis NIPT system. Dr. Gautier will outline his laboratory’s experience of the installation process, training, and the day-to-day activities involved in operating the system.
Vanadis® NIPT is in development